Bruske welcomes NDP commitment to end profiteering off of seniors' care
ST. JOHN'S, Newfoundland and Labrador, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Canadian Labour Congress president Bea Bruske made the following statement today:
"Decades of cuts and privatization in the long-term care sector have had tragic consequences during this crisis.
"Early in the pandemic, long-term care homes accounted for four out of every five COVID-19 related deaths in Canada. In Ontario, the Commission into long-term care said for-profit companies should no longer be in charge of care.
"The for-profit model has clearly failed seniors and their families. We welcome Jagmeet Singh and the New Democrats' commitment to take profit out of long-term care.
"For years, long-term care workers, unions and advocates for senor's health care have demanded systemic change to a broken system.
"Canada's unions have been fighting for long-term care to be offered as a public service. This means making major changes to Canada's long-term care sector, including regulating long-term care under the Canada Health Act."
Canada's unions have been calling on governments to address the failings COVID-19 exposed in long-term care by:
Bringing long-term care into the public system and regulating it under the Canada Health Act;
Removing private, for-profit businesses from the sector;
Requiring proper staffing and health and safety protections for workers; and
Permanently raising wages and benefits for long-term care workers to match the value of the work.
Full recommendations on Long-term care can be found here.
To arrange an interview, please contact: CLC Media Relations [email protected] 613-355-1962
Genmab A/S today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma...
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...
Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type...
Taseko Mines Limited (LSE: TKO) ("Taseko" or the "Company") announced today that operations at the Company's Gibraltar Mine have been suspended.
Collective bargaining with Gibraltar's union representatives has been ongoing in recent weeks, and...